Organization: Structural Genomics Consortium

Structural Genomics Consortium expanding clinical and patient reach with new Phase IV funding

Canadian funding for the Toronto-based Structural Genomics Consortium (SGC) has been renewed, injecting $33 million into the ground breaking open innovation organization that determines the three-dimensional structure of proteins related to human diseases. The fourth phase of the public-private SGC will see an expansion its collaborative network to include disease and patient foundations while partnering with clinicians and research hospitals to validate new targets for drug discovery by testing its chemical probes on patients.

Editorial 31-7

The National Research Council is embarking on a re-alignment of its core strengths by reaching out to academia and other players in the federal innovation system (see lead article). NEOMED is making major strides retaining critical pharmaceutical talent in the Montreal region and its actively considering a third site for its potent combination of research expertise and business collaboration

Merck joins SGC, contributes $7.5 million

Merck & Co Inc is contributing $7.5 million to the Structural Genomics Consortium (SGC) as its newest corporate member. Merck’s decision to join the SGC was prompted by the organization’s status as a public-private partnership and its pioneering efforts to use open source intellectual property for moving technologies and medications into proprietary drug discovery programs.…

Merck joins SGC, contributes $7.5 million

Merck & Co Inc is contributing $7.5 million to the Structural Genomics Consortium (SGC) as its newest corporate member. Merck’s decision to join the SGC was prompted by the organization’s status as a public-private partnership and its pioneering efforts to use open source intellectual property for moving technologies and medications into proprietary drug discovery programs.…

SGC launches third phase with $49.9 million in funding

The Toronto-based Structural Genomics Consortium (SGC) has received $48.9 million to launch its third four-year phase. The funding is 30% less than in previous phases due primarily to the closure of the SGC laboratory at Karolinska Institutet in suburban Stockholm last June. The funding — 45% of which comes from commercial entities — will support…

Structural Genomics Consortium funding announced

Complete funding for the second phase of the Structural Genomics Consortium has been announced, with 13 partners (including three pharmaceutical firms) providing more than $105 million. The consortium — led by Dr Aled Edwards at the Univ of Toronto with three nodes in Toronto, the Univ of Oxford and the Karolinska Institutet — is dedicated…

UK-Canada consortium to explore human proteins

A $95-million UK-Canada partnership billed as the largest international research project ever funded in Canada will spend the next three years determining the three-dimensional structure of more than 350 human proteins. The Structural Genomics Consortium (SGC) is led by Dr Aled Edwards, a leading expert in proteomics and structural genomics research with the Bant-ing and…